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Abstract
Background:  Rivastigmine, a butyl- and acetylcholinesterase inhibitor, is approved for
symptomatic treatment of Alzheimer's disease (AD). Data supporting the safety and efficacy of
second-generation cholinesterase inhibitors, such as rivastigmine, are available for treatment up to
1 year, with limited data up to 2 1/2 years. The purpose of this report is to present safety and
effectiveness data for rivastigmine therapy in patients with mild to moderately severe AD receiving
treatment for up to 5 years.
Methods:  An observational approach was used to study 37 patients with originally mild to
moderate AD receiving rivastigmine as a therapy for AD in an open-label extension (ENA713, B352
Study Group, 1998).
Results: The initial trial demonstrated rivastigmine was well-tolerated and effective in terms of
cognition, global functioning and activities of daily living. In this open label extension, high-dose
rivastigmine therapy was safe and well tolerated over a 5-year period. Two thirds of the
participants still enrolled at week 234 were in the original high-dose rivastigmine group during the
double-blind phase, suggesting that early therapy may confer some benefit in delaying long-term
progression of symptoms.
Conclusions: Long-term cholinesterase inhibition therapy with rivastigmine was well tolerated,
with no dropouts due to adverse effects past the initial titration period. Early initiation of
treatment, with titration to high-dose therapy, may have an advantage in delaying progression of
the illness.
Background
Alzheimer's disease (AD) is the most common form of
dementia affecting elderly people in the United States.
Prevalence is 1% to 2% at age 65 years, but increases
markedly to 35% or greater by age 85. Because of a demo-
graphic shift toward a more aged population, the percent-
age of affected individuals is rapidly increasing. This trend
is expected to continue for the foreseeable future. There-
fore, accurate and timely diagnosis and effective treat-
ments are critical to optimal outcomes over the 8- to 10-
year course of the illness [1].
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Traditionally, a probable diagnosis of AD was accom-
plished by history, clinical examination, neuroimaging,
and neuropsychological and laboratory testing to rule out
treatable causes for the patient's symptoms and to differ-
entiate AD from other possible causes of dementia [2,3].
Much effort has gone into defining risk factors for the
development and progression of Alzheimer's dementia, as
well as to identify biological markers for the disease. Clin-
ical-demographic variables that are consistently associ-
ated with AD in prior studies include family history of AD,
age, and Down's syndrome [1,3]. None of these variables
has been demonstrated to affect the rate of disease pro-
gression or show any utility in defining subgroups that
may be more amenable to therapy.
Currently, predominant symptoms of dementia are
treated primarily with second-generation cholinesterase
(ChE) inhibitors. These drugs have demonstrated efficacy,
as measured by cognitive, behavioral, and functional out-
comes, in randomized, placebo-controlled clinical trials,
the majority of which have been of 6 months' duration [4-
6]. In an open-label extension study of the cholinesterase
inhibitor donepezil, Doody et al [7] concluded that
donepezil was safe and effective for treating the symptoms
of mild to moderate AD for up to 2 1/2 years. Cognitive,
behavioral, and functional outcomes in patients treated
with ChE inhibitors over the longer term are of great inter-
est given the substantial social and economic implications
of AD, which has a course that averages 8 to 10 years. Due
to their relatively recent approval, however, longer-term
data on the clinical benefits and/or limitations of ChE
inhibitor therapy in AD patients is virtually nonexistent
[8].
Rivastigmine's approval by the FDA in 2000 was sup-
ported by several pivotal trials, including a randomized
US trial (ENA 713 B352)[5]. In this pivotal trial, 699
patients with mild to moderately severe AD were rand-
omized to high dose rivastigmine (6–12 mg/day), low
dose (1–4 mg/day) or placebo with a 7 week fixed dose-
titration phase followed by a flexible dosing phase during
weeks 8–26. Results of the 26-week open-label extension
of this study found that at 52 weeks, patients originally
treated with 6–12 mg/day rivastigmine had significantly
better cognitive function than patients originally treated
with placebo [9]. In this paper the authors present
descriptive findings for a cohort of 37 patients who partic-
ipated in the long-term open-label extension of the
ENA713B352 rivastigmine trial.
Much work remains to be done to more definitively
answer questions about when to start therapy, which
patients are most likely to benefit, what constitutes clini-
cally relevant beneficial effects over the longer term, and
when these drugs are no longer clinically effective. Con-
sideration should also be given to withdrawal of therapy.
Findings presented in this article will add to the current
limited dataset for long-term efficacy and outcomes with
cholinesterase inhibitor therapy for persons with proba-
ble AD.
This report describes our experience in following the
cohort of patients at our center with AD treated with the
ChE inhibitor rivastigmine (a medication that inhibits
both butyl- and acetylcholinesterase) as part of the ENA
713 B352 pivotal trial for a period up to 5 years.
Methods
Data in this analysis came from a subgroup of 37 patients
with originally mild- to moderate-stage (defined by a
Mini-Mental State Examination [MMSE] score of 10 to 26)
AD followed at a large Mid-Western university site in a 26-
week, prospective, randomized, double-blind, placebo-
controlled, parallel-group study of rivastigmine as therapy
for AD conducted at 22 research sites across the United
States (ENA713, B352 Study Group, 1998) [5].
Patients were enrolled according to previously described
inclusion criteria [5]. Of note, this study allowed rather
broad inclusion of AD patients with other comorbid ill-
nesses; presumably this would allow this cohort to more
closely mirror real-world populations. The study was con-
ducted in accordance with ethical standards of the institu-
tional committee on human experimentation and with
the Helsinki Declaration of 1975, revised 1983. The initial
study protocol was therefore reviewed in our center by the
institutional review board and all patients or caregivers
consented to inclusion based on appropriate informed
consent. Additional consent was obtained for the open-
label extension of the study.
Cholinesterase inhibitor treatment
Immediately following the double-blind phase of the
study, open-label rivastigmine was flexibly titrated over a
12-week time period to a maximum tolerated dosage of
up to 6 mg BID. By the end of the 12 week titration 25 par-
ticipants were on 4–6 mg. of rivastigmine and 11 partici-
pants had dropped from the study. One participant
remained on a 2 mg. dose and dropped from the study
between weeks 52 and 78.
Assessment of treatment response
Outcomes measures included the Alzheimer's Disease
Assessment Scale-cognitive subscale (ADAS-cog) and the
Clinician's Interview-Based Impression of Change, with
caregiver input (CIBIC-Plus). Ability to carry out activities
of daily living (ADL) was assessed by the Progressive Dete-
rioration Scale (PDS). Disease-staging measures included
the Geriatric Deterioration Scale (GDS) and the MMSE. In
the open-label phase of the study, efficacy evaluationsBMC Geriatrics 2005, 5:3 http://www.biomedcentral.com/1471-2318/5/3
Page 3 of 7
(page number not for citation purposes)
were performed every 6 to 8 weeks for titration and early
maintenance, and every 26 weeks for the next 5 to 6 years.
Statistical analysis
These data are predominantly descriptive, with analyses
including Kaplan- Meier survival plots when appropriate.
All statistical analyses on our single center extension were
performed at our center using SPSS. Subgroup analyses by
initial treatment randomization were also performed.
Results
Demographics and population
Twenty-one Caucasian women and 11 Caucasian men
participated in the open label extension of this pivotal
study. Twenty-two participants reported a family history
of AD. Selected demographic and baseline characteristics
of the subsample are presented in Table I. Of the 32
patients, 11 were originally randomized to the high dose
(6–12 mg/day) group, 10 to the low dose group, and 11
to placebo. Five of the patients in the cohort chose not to
participate in the extension.
A total of 25 patients during the 5-year term eventually
withdrew from the study. Reasons for termination, strati-
fied by original group during the double-blind phase, are
summarized in Figure 1. The most frequent reason for ter-
mination of participants initially randomized to the high-
dose group was the lack of availability of free rivastigmine
following FDA approval, which had been provided at pre-
launch at no charge as part of the clinical study. It is of
interest that no deaths occurred in the group initially ran-
domized to high-dose rivastigmine during the initial dou-
ble-blind, placebo-controlled trial. Furthermore, disease
severity, as measured by the GDS, was greater in the orig-
inal high-dose group (mean = 4.0; median = 4.0) as com-
pared with the low-dose (mean = 3.7; median = 3.5) and
placebo groups (mean = 3.4, median = 3.0). A total of 8
terminations were due to withdrawal of consent (n = 3) or
caregiver discontinuation (n = 5). Five of the 8 were in the
original placebo group. Seven patients withdrew because
of adverse events; 2 each in the original low-dose and pla-
cebo groups (57%) and 3 in the original high-dose group
(43%). Treatment failure was cited as the reason for termi-
nation of one 69-year-old man in the original placebo
group. His baseline MMSE score was 21, and his final
MMSE score at week 26 was 17. No other patients with-
drew as a result of treatment failure.
Of the 4 patients who withdrew from the study due to dis-
ease progression, 3 were men between the ages of 57 and
Table 1: Selected baseline and demographic characteristics (N = 
32).
Characteristic Mean (SD)
Age (y) 71.8 (7.5)
Length of symptoms (mo)* 29.6 (18.3)
Baseline MMSE 21.3 (4.1)
Baseline GDS 3.7 (0.78)
MMSE = Mini-Mental Status Examination; GDS = Geriatric 
Deterioration Scale.
*Length of symptoms prior to enrollment in the double-blind study.
Reason for termination stratified by original group Figure 1
Reason for termination stratified by original group.
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64 years. The 57-year-old man was in the original high-
dose group, with a baseline MMSE score of 16 and an
MMSE score of 0 at the 234-week data collection. The
other two male participants were aged 62 and 64 years
with baseline MMSE scores of 22 and 20, respectively. The
62-year-old man in the original low-dose group withdrew
at week 104 with an MMSE score of 9; the 64-year old man
in the original high-dose group withdrew at week 156
with an MMSE score of 11. Interestingly, the 76-year-old
woman in the original low-dose group, with a baseline
MMSE score of 22, withdrew after the 26-week data collec-
tion (MMSE = 21).
Quantitative (objective) analysis
The Kaplan-Meier survival analysis, shown in Figure 2,
illustrates time to dropout from week 26 to week 234. The
survival curve reveals a relatively steep decline in partici-
pation in the first 9 months of open-label extension,
mostly related to adverse events (AEs), since almost all
AEs causing discontinuation occurred during this phase,
followed by a "flattening" of the curve. Fourteen partici-
pants were still taking high-dose rivastigmine at 2 years,
12 participants at 3 years, and 10 participants at 4 years.
Of the subjects starting open-label rivastigmine, 25% were
still participating at week 234. Of the 8 subjects still par-
ticipating, 5 were female and only 1 reported a family his-
tory of AD. Interestingly, this group was characterized by
a broad age range (57–85 years), a broad range of baseline
MMSE scores (15–26), and by the fact that 5 of the 8
remaining participants at week 234 were in the original
high-dose rivastigmine group.
For the end point defined as a 5-point drop from the base-
line MMSE score, the group mean was 94 weeks. However,
an age-related observation was noted such that the mean
time to a 5-point drop from baseline MMSE for the ≤ 70
age group was 67 weeks as compared with 122 weeks for
the >70 years age group. A similar trend was observed for
scores on the ADAS-cog. For the group as a whole, mean
time to a 4-point deterioration on the ADAS-cog was 84
weeks; with a mean of 70 weeks for the younger group and
104 weeks for the older group. [In the original study,
Mean scores on the Alzheimer's Disease Assessment Scale- cognitive subscale (ADAS-cog) for weeks 26–234 Figure 3
Mean scores on the Alzheimer's Disease Assessment Scale-
cognitive subscale (ADAS-cog) for weeks 26–234.
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mean age across the 22 research sites was 74.5 years; mean
age for participants in this report was 71.8 years]
Figures 4 through 8 summarize mean scores for the ADAS-
cog, CIBIC, GDS, PDS, and MMSE from week 26 through
week 234. As expected, mean values for cognitive and
functional status decline over time; however, significant
within subject variability is present.
Qualitative analysis
When evaluating qualitative data, it is important to exam-
ine particular patients in terms of the data collected and
treatment response at end of study. Data for the youngest
man and the elderly woman, considered side-by-side,
seem counterintuitive. Part of the explanation, however,
may rest with the caregivers' experiences with and beliefs
about the patients. This information can be accessed by
reviewing the "symptoms most troubling" item from the
CIBIC-Plus. This item asks, "With respect to the above
symptoms, which are the biggest problems for you and/or
other caregivers?" The spouse of the 57-year-old man
reported that the "symptoms most troubling" for her were
the patient's "selective difficulties and his attitude prob-
lem" (week 104, MMSE = 11) and that the patient
"doesn't try" (week 130, MMSE = 7). These comments
suggest a lack of acceptance of the patient's diagnosis and
a lack of belief regarding the patient's documented decline
that could explain continued clinic visits until, at week
234, the patient's MMSE score was 0. In contrast, the car-
egiver for the 76-year-old woman cited the fact that the
patient "doesn't want to leave the house" (week 12) and
the patient's anxiety about coming to clinic appointments
(week 26) as the "most troubling" symptoms. These com-
ments suggest that the caregiver was encountering patient
resistance and observing patient distress, which were exac-
erbated by efforts to participate in the study. Therefore,
further clinic visits were declined. Retrospectively, it is
impossible to determine how the caregiver's beliefs and
experience with the patient affect perceptions about dis-
ease status, treatment response, and decisions to continue
or terminate treatment. These are interesting hypothesis-
generating observations that should be explored in future
investigations.
Mean scores on Geriatric Deterioration Scale for weeks 26– 234 Figure 5
Mean scores on Geriatric Deterioration Scale for weeks 26–
234.
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Discussion
Limited data are available on the tolerability and effective-
ness of cholinesterase inhibitor therapy for periods up to
3 years [4-7], but nothing has been reported in the litera-
ture concerning the percentages of patients remaining on
therapy and its effect beyond this time point. This study
adds to the limited long term data on patients treated with
high-dose rivastigmine therapy by reporting descriptive
data for up to 5 years. Findings presented in this report
indicate that, in this sample of patients, high-dose
rivastigmine therapy was well tolerated over a 5-year
period.
Of note, approximately two thirds of the participants still
enrolled at week 234 were in the original high-dose
rivastigmine group during the double-blind phase; this
finding suggests that early therapy with rivastigmine may
confer some benefit in delaying long-term progression of
symptoms, as has been previously suggested by analysis of
the combined 26 weeks of double-blind and first 26
weeks of open-label data from the B352 US trial [9].
Throughout the initial 26-week double-blind portion,
patients receiving placebo steadily deteriorated, while
those treated with high-dose rivastigmine were able to
maintain their baseline level of performance on the
ADAS-Cog [5]. This approximated a delayed-start design
for the open-label portion, which demonstrated that
patients who started rivastigmine late never "caught up"
with patients who had been on high-dose rivastigmine
from the beginning of the trial. This suggests a disease-
progression-delaying effect of the drug, which may allow
this population to maintain their autonomy for a longer
period of time. However, it is important to emphasize the
limitations of this data; the analysis was retrospective, the
sample was small, there were significant numbers of drop-
outs, and the availability of free rivastigmine ceased with
FDA approval which occurred near to the end of the study
Conclusions
In summary, long-term therapy with the ChE inhibitor
rivastigmine was well tolerated with no dropouts due to
adverse effects past the first 9 months of the open-label
extension. In contrast to the generally reported commu-
nity experience of relatively brief duration of therapy with
ChE inhibitors in AD, 25% of patients in this study were
still taking rivastigmine by the end of 5 years. Of interest
is the multifactorial nature of reasons for treatment dis-
continuation. Only 1 of these patients withdrew from the
study because of perceived treatment failure over the 5-
year period. Disease progression accounted for the with-
drawal of 4 patients.
These results are informative both for the duration of
treatment, and because the majority of the patients who
continued treatment during this 5 year period were from
the group originally titrated up to a high dose during the
initial double-blind phase. Given that the sample size
prohibits significance testing, these data suggest that
rivastigmine therapy may be sustained over long periods
of time in a significant percentage of patients with AD,
and that high-dose therapy, particularly when begun
early, may have an advantage in delaying the progression
of the illness.
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